Evidence map›Paper›PMID 33753821›Full record

ArticleScientific reports2021

Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis.

Anne-Christine Bay-Jensen, Asger Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Bente Juhl Riis, Claus Christiansen, Martin Michaelis, Hans Guehring, Christoph Ladel, Morten A Karsdal

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Anne-Christine Bay-JensenImmuno-Science, Nordic Bioscience, Biomarkers and Research, Herlev Hovedgade, 2730, Herlev, Denmark. acbj@nordicbio.com.
Asger BihletNBCD A/S, Herlev Hovedgade 82, 2730, Herlev, Denmark.
Inger ByrjalsenNordic Bioscience, Clinical Development, Herlev Hovedgade 82, 2730, Herlev, Denmark.
Jeppe Ragnar AndersenNBCD A/S, Herlev Hovedgade 82, 2730, Herlev, Denmark.
Bente Juhl RiisNBCD A/S, Herlev Hovedgade 82, 2730, Herlev, Denmark.
Claus ChristiansenNordic Bioscience, Clinical Development, Herlev Hovedgade 82, 2730, Herlev, Denmark.
Martin MichaelisMerck KGaA, Translational Innovation Platform Immunology, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Hans GuehringMerck KGaA, Global Patient Safety, Frankfurter Strasse 250, 64293, Darmstadt, Germany.
Christoph LadelBioBone B.V., Amsterdam, Netherlands.
Morten A KarsdalImmuno-Science, Nordic Bioscience, Biomarkers and Research, Herlev Hovedgade, 2730, Herlev, Denmark.
Nordic Bioscience (Denmark) · DKHerlev Hospital · DKMerck (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM levels have shown to be associated with disease activity and response to treatment in rheumatoid arthritis (RA). We investigated the level of blood CRPM in OA compared to RA using data from two phase III knee OA and two RA studies (N = 1591). Moreover, the association between CRPM levels and radiographic progression was investigated. The mean CRPM levels were significantly lower in OA (8.5 [95% CI 8.3-8.8] ng/mL, n = 781) compared to the RA patients (12.8 [9.5-16.0] ng/mL, n = 60); however, a significant subset of OA patients (31%) had CRPM levels (≥ 9 ng/mL) comparable to RA. Furthermore, OA patients (n = 152) with CRPM levels ≥ 9 ng/mL were more likely to develop contra-lateral knee OA assessed by X-ray over a two-year follow-up period with an odds ratio of 2.2 [1.0-4.7]. These data suggest that CRPM is a blood-based biochemical marker for early identification OA patients with an inflammatory phenotype.

Indexed as

AdultAgedArthritis, RheumatoidBiomarkersCohort StudiesC-Reactive ProteinDisease SusceptibilityFemaleHumansIncidenceMaleMiddle AgedOdds RatioOligopeptidesOsteoarthritis, KneeROC CurveBiomarkerscatch-relaxing peptide (Mytilus)C-Reactive ProteinOligopeptides

Identifiers

PMID33753821
PMCPMC7985384
OpenAlexW3139082473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.